Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2027-12-15
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the stringent Complete Response (sCR) rate by the end of two
cycles of induction treatment, defined as the proportion of patients who have achieved sCR,
according to International Myeloma Working Group (IMWG) criteria, by the end of two cycles of
induction treatment.